💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Carvedilol Phosphate

CHEMBL1201167 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
1027.0 g/mol
LogP
—
Phase
4

The phosphate salt form of carvedilol shares the same nonselective beta and alpha-1 adrenergic blocking properties as the parent drug, used in treating heart failure and hypertension. The extended-release phosphate formulation allows for once-daily dosing, which may improve patient adherence. It carries the same monitoring requirements as carvedilol, including for bradycardia and hypotension.

Молекулярная масса

1027,0000 g/mol

TPSA

308,00 Ų

Терапевтические области

Hypertension Breast Cancer Heart Failure

Механизм действия

Non-selective beta-blocker with alpha-1 blocking activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Non-selective beta-blocker with alpha-1 blocking activity.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.O=P(O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C24H26N2O4.H3O4P/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20;1-5(2,3)4/h2-12,17,25-27H,13-16H2,1H3;(H3,1,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
C48H60N4O17P2

                    

                    
                    

                        
HBD / HBA

                        
13 / 19

                    

                    
                    

                        
Вращаемые Связи

                        
20

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
71

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
The phosphate salt form of carvedilol shares the same nonselective beta and alpha-1 adrenergic blocking properties as the parent drug, used in treating heart failure and hypertension. The extended-release phosphate formulation allows for once-daily dosing, which may improve patient adherence. It carries the same monitoring requirements as carvedilol, including for bradycardia and hypotension.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Non-selective beta-blocker with alpha-1 blocking activity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Carvedilol Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201167.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11954344.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.